Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Acquisitions (2023 - 2024)

Cytek Biosciences (CTKB) has disclosed Acquisitions for 2 consecutive years, with $471000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Acquisitions changed N/A year-over-year to $471000.0, compared with a TTM value of $471000.0 through Dec 2024, down 98.95%, and an annual FY2024 reading of $471000.0, down 98.95% over the prior year.
  • Acquisitions was $471000.0 for Q4 2024 at Cytek Biosciences, up from $1000.0 in the prior quarter.
  • Across five years, Acquisitions topped out at $44.9 million in Q1 2023 and bottomed at $1000.0 in Q3 2023.